Drug Topics January 27, 2026
Community pharmacies continue to operate in unchartered territory regarding Medicare drug price negotiations as the new IRA statute becomes an unavoidable reality for business operations.
Moving into 2026, the Inflation Reduction Act (IRA) is officially shifting from a legislative policy to a daily reality for pharmacists. For the first time, negotiated Maximum Fair Prices (MFPs) have taken effect for 10 high-spend Medicare Part D drugs, including critical medications like Eliquis, Jardiance, and Januvia. This landmark change marks a fundamental pivot for pharmacy businesses, transitioning the industry from traditional dispensing models to a new era of active financial navigation.
The introduction of these negotiated prices has brought about a significant operational shift. To facilitate these new fair prices, the government has...
Today's Sponsors
Today's Sponsor